Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Jeffrey Ronn

Pulmonary Disease Surprise, AZ Medical Doctor

NPI 1922097773 CMS profile 87418

18731 N. Reems Rd, #680, Surprise, AZ 85374

Open in the dashboard

General payments

$7,258

375 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Jeffrey Ronn of Surprise, AZ is reported in the CMS Open Payments database as having received $7,258 across 375 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 74th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $54 3
2022 General $319 17
2021 General $2,484 121
2020 General $1,912 93
2019 General $2,489 141

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jeffrey Ronn
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Jeffrey Ronn were reported at $0. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Jeffrey Ronn Pulmonary Disease median Middle half National median
2019 $2,489 $377 $109–$1,340 $163
2020 $1,912 $230 $56–$907 $114
2021 $2,484 $269 $68–$1,072 $132
2022 $319 $390 $100–$1,457 $149
2023 $54 $419 $114–$1,659 $160
2024 $0 $476 $123–$1,818 $164
2025 $0 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. GlaxoSmithKline, LLC. $1,155 71 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $998 43 payments
  3. AstraZeneca Pharmaceuticals LP $586 29 payments
  4. Actelion Pharmaceuticals US, Inc. $556 26 payments
  5. Harmony Biosciences LLC $361 13 payments
  6. Genentech USA, Inc. $356 22 payments
  7. Advanced Respiratory, Inc $332 17 payments
  8. Mylan Specialty L.P. $326 18 payments
  9. Philips Electronics North America Corporation $292 14 payments
  10. Electromed, Inc. $239 16 payments
  11. Other $2,056 106 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $7,258 375 payments
Products named General payments · program years 2019–2023
  1. SPIRIVA RESPIMAT $813 35 payments
  2. TRELEGY ELLIPTA $623 39 payments
  3. OPSUMIT $556 26 payments
  4. UPTRAVI $466 22 payments
  5. STIOLTO RESPIMAT $397 17 payments
  6. Wakix $361 13 payments
  7. Esbriet $356 22 payments
  8. DUPIXENT $343 17 payments
  9. SYMBICORT $327 16 payments
  10. OFEV $274 11 payments
  11. Other $5,275 273 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

375 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record